These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 3920548)

  • 1. Time-dependent interaction between phenytoin and valproic acid.
    Riva R; Albani F; Contin M; Perucca E; Ambrosetto G; Gobbi G; Santucci M; Procaccianti G; Baruzzi A
    Neurology; 1985 Apr; 35(4):510-5. PubMed ID: 3920548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluctuations of unbound and total phenytoin concentrations during the day in epileptic patients on valproic acid comedication.
    May T; Rambeck B
    Ther Drug Monit; 1990 Mar; 12(2):124-8. PubMed ID: 2107607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenytoin--valproic acid interaction in rhesus monkey.
    Koch KM; Ludwick BT; Levy RH
    Epilepsia; 1981 Feb; 22(1):19-25. PubMed ID: 6781887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Derivation and evaluation of an equation for prediction of free phenytoin concentration in patients co-medicated with valproic acid.
    Haidukewych D; Rodin EA; Zielinski JJ
    Ther Drug Monit; 1989; 11(2):134-9. PubMed ID: 2497562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diurnal fluctuations in free and total plasma concentrations of valproic acid at steady state in epileptic patients.
    Riva R; Albani F; Cortelli P; Gobbi G; Perucca E; Baruzzi A
    Ther Drug Monit; 1983 Jun; 5(2):191-6. PubMed ID: 6410545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of valproate coadministration and hypoalbuminemia on the serum-free phenytoin concentration in patients with severe motor and intellectual disabilities.
    Mamiya K; Yukawa E; Matsumoto T; Aita C; Goto S
    Clin Neuropharmacol; 2002; 25(4):230-3. PubMed ID: 12151911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein binding.
    Tasaki K; Minami T; Ieiri I; Ohtsubo K; Hirakawa Y; Ueda K; Higuchi S
    Brain Dev; 1995; 17(3):182-5. PubMed ID: 7573757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic valproic acid therapy and incidence of increases in venous plasma ammonia.
    Haidukewych D; John G; Zielinski JJ; Rodin EA
    Ther Drug Monit; 1985; 7(3):290-4. PubMed ID: 3931312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diurnal oscillations in plasma protein binding of valproic acid.
    Patel IH; Venkataramanan R; Levy RH; Viswanathan CT; Ojemann LM
    Epilepsia; 1982 Jun; 23(3):283-90. PubMed ID: 6806086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring free valproic acid in epilepsy patients medicated with coanticonvulsants.
    Haidukewych D; Rodin EA
    Ther Drug Monit; 1982; 4(2):209-12. PubMed ID: 6808716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations and enzyme induction in epileptic children treated with phenytoin and valproate.
    de Wolff FA; Peters AC; van Kempen GM
    Neuropediatrics; 1982 Feb; 13(1):10-3. PubMed ID: 6123089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents.
    Steinborn B; Galas-Zgorzalewicz B
    Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of therapeutic drug monitoring of antiepileptic drugs.
    Irshaid YM; Hamdi AA; Al Homrany M
    Int J Clin Pharmacol Ther; 2003 Mar; 41(3):126-31. PubMed ID: 12665161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproic acid-phenytoin interaction.
    Friel PN; Leal KW; Wilensky AJ
    Ther Drug Monit; 1979; 1(2):243-8. PubMed ID: 122160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of total and free phenytoin serum concentrations measured by high-performance liquid chromatography and standard TDx assay: implications for the prediction of free phenytoin serum concentrations.
    May TW; Rambeck B; Jürges U; Blankenhorn V; Jürgens U
    Ther Drug Monit; 1998 Dec; 20(6):619-23. PubMed ID: 9853976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nomogram for the prediction of unbound phenytoin concentrations in patients on a combined treatment of phenytoin and valproic acid.
    May TW; Rambeck B; Nothbaum N
    Eur Neurol; 1991; 31(1):57-60. PubMed ID: 2015840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate.
    Della Paschoa OE; Voskuyl RA; Danhof M
    Br J Pharmacol; 1998 Dec; 125(7):1610-6. PubMed ID: 9884091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus.
    Gatti G; Crema F; Attardo-Parrinello G; Fratino P; Aguzzi F; Perucca E
    Ther Drug Monit; 1987 Dec; 9(4):389-91. PubMed ID: 3122377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of free levels of phenytoin and carbamazepine in patients comedicated with valproic acid.
    Ratnaraj N; Hjelm M
    Ther Drug Monit; 1995 Aug; 17(4):327-32. PubMed ID: 7482684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.